AYTU

SEC source: 0000912282-23-000296 · form4.xml · derivative · entry 1

Oki Mark K · CIK 0001491847 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Shares · 13,000 shares

Expires 2033-08-12

F1 · derivative.exercise_date: The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024.

SEC source: 0000912282-23-000302 · form4.xml · nonDerivative · entry 1

LIU VIVIAN H · CIK 0001203467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,841

F1 · shares: Grant of restricted shares, which vest as follows: 1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024.

F2 · balance_after: Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023.

SEC source: 0000912282-23-000305 · form4.xml · derivative · entry 1

Disbrow Jarrett · CIK 0001640724 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Shares · 7,000 shares

Expires 2033-08-12

F1 · derivative.exercise_date: The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024.

SEC source: 0000912282-23-000303 · form4.xml · nonDerivative · entry 1

JAIN ABHINAV · CIK 0001981291 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,500

F1 · shares: Grant of restricted shares, which vest as follows: 1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months, beginning on November 11, 2024.

SEC source: 0000912282-23-000301 · form4.xml · nonDerivative · entry 1

Donofrio John Jr. · CIK 0001679841 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,262

F1 · shares: Grant of restricted shares, which vest as follows: 1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024.

F2 · balance_after: Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023.

SEC source: 0000912282-23-000300 · form4.xml · nonDerivative · entry 1

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,940

F1 · shares: Grant of restricted shares, which vest as follows: 1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024.

F2 · balance_after: Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023.

SEC source: 0000912282-23-000299 · form4.xml · derivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Shares · 35,000 shares

Expires 2033-08-12

F1 · derivative.exercise_date: The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024.

SEC source: 0000912282-23-000297 · form4.xml · derivative · entry 1

BROOKE CHRISTOPHER · CIK 0001953013 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Shares · 7,000 shares

Expires 2033-08-12

F1 · derivative.exercise_date: The options vest as follows: 1/3 vest on August 11, 2024, with the remaining options vesting in 24 equal monthly installments, beginning September 11, 2024.

SEC source: 0000912282-23-000295 · form4.xml · derivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Shares · 7,000 shares

Expires 2033-08-12

F1 · derivative.exercise_date: The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024.

SEC source: 0000912282-24-000752 · form4.xml · nonDerivative · entry 1

LIU VIVIAN H · CIK 0001203467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,325

F1 · shares: Grant of restricted shares, which vest as follows: 1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning November 11, 2024.

F2 · balance_after: Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023.

SEC source: 0000912282-23-000164 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commerical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,459

Underlying: Common Shares · 208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

SEC source: 0000912282-23-000164 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commerical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

SEC source: 0000912282-23-000137 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commerical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,935

F1 · price: The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.869, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

SEC source: 0000912282-23-000133 · form4.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,591

F1 · price: The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · balance_after: Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.

SEC source: 0000912282-23-000135 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commerical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,667

Underlying: Common Shares · 833 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Represents restricted stock units ("RSU"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · shares: Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.

F2 · derivative.exercise_date: Represents restricted stock units ("RSU"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F2 · derivative.expiration_date: Represents restricted stock units ("RSU"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · derivative.underlying_shares: Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.

F1 · balance_after: Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.

SEC source: 0000912282-23-000135 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commerical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,935

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023.

SEC source: 0001567619-23-002409 · doc1.xml · nonDerivative · entry 1

LIU VIVIAN H · CIK 0001203467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,825

F1 · shares: Represents restricted share grant. One-third of the restricted shares shall vest on July 1, 2023; the remaining restricted shares shall vest quarterly thereafter, at 1/8th of the remaining grant, with full vesting on July 1, 2025.

F2 · balance_after: Total reflects 1-to-20 reverse stock split effected by the Issuer on January 6, 2023.

SEC source: 0001567619-22-021997 · doc1.xml · nonDerivative · entry 1

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,805

F1 · shares: On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

F1 · price: On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

SEC source: 0001567619-22-022004 · doc1.xml · nonDerivative · entry 1

Donofrio John Jr. · CIK 0001679841 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,267

F1 · shares: On December 21, 2022, the reporting person and the Issuer determined to rescind 187,804 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

F1 · price: On December 21, 2022, the reporting person and the Issuer determined to rescind 187,804 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

SEC source: 0001567619-22-022001 · doc1.xml · nonDerivative · entry 1

Cantrell Gary · CIK 0001679246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,089

F1 · shares: On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

F1 · price: On December 21, 2022, the reporting person and the Issuer determined to rescind 40,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

SEC source: 0001567619-22-021999 · doc1.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,151,877

F1 · shares: On December 21, 2022, the reporting person and the Issuer determined to rescind 80,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

F1 · price: On December 21, 2022, the reporting person and the Issuer determined to rescind 80,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer.

SEC source: 0001567619-22-021900 · doc1.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,231,877

F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.213 to $0.23, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

SEC source: 0001567619-22-021899 · doc1.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,056

SEC source: 0001654954-22-015598 · section16.xml · nonDerivative · entry 1

Oki Mark K · CIK 0001491847 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,000

SEC source: 0001654954-22-015599 · section16.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,119,506

SEC source: 0001567619-22-020920 · doc1.xml · nonDerivative · entry 1

Oki Mark K · CIK 0001491847 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,000

SEC source: 0001567619-22-020922 · doc1.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,119,506

SEC source: 0001567619-22-013590 · doc1.xml · nonDerivative · entry 1

LIU VIVIAN H · CIK 0001203467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

F1 · shares: Represented restricted share grant. One-third of the restricted shares shall vest on July 1, 2023; the remaining restricted shares shall vest quarterly thereafter, at 1/8th of the remaining grant, with full vesting on July 1, 2025.

SEC source: 0001567619-22-001304 · doc1.xml · nonDerivative · entry 1

Oki Mark K · CIK 0001491847 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: Restricted share grant. One-third of the restricted shares shall vest on January 17, 2023; the remaining restricted shares shall vest quarterly thereafter, at 1/12th of the original grant, with full vesting on January 17, 2025.

SEC source: 0001567619-21-008232 · doc1.xml · nonDerivative · entry 1

MACALUSO MICHAEL · CIK 0001096423 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,079

F1 · shares: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0001567619-21-008238 · doc1.xml · nonDerivative · entry 1

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,805

F1 · shares: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0001567619-21-008230 · doc1.xml · nonDerivative · entry 1

Donofrio John Jr. · CIK 0001679841 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,071

F1 · shares: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0001567619-21-008229 · doc1.xml · nonDerivative · entry 1

Cantrell Gary · CIK 0001679246 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,089

F1 · shares: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0001567619-21-008228 · doc1.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 897,506

F1 · shares: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). (4) At the Compensation Committee's discretion based on the Company achieving certain revenue milestones and the successful integration of future acquisitions. The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). (4) At the Compensation Committee's discretion based on the Company achieving certain revenue milestones and the successful integration of future acquisitions. The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0001567619-21-007912 · doc1.xml · nonDerivative · entry 1

McLaughlin Gerald W. · CIK 0001495412 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,401

F1 · shares: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0001567619-21-007909 · doc1.xml · nonDerivative · entry 1

Hecht Beth · CIK 0001652410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,052

F1 · shares: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below).The RSUs vest as follows, and have no voting or dispositive rights until vested: one year vest from date of grant, April 8, 2021 such that the RSUs will be fully vested on April 8, 2022, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0001567619-21-007654 · doc1.xml · nonDerivative · entry 1

Eisenstadt Richard I · CIK 0001515806 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,734

F1 · security: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

F1 · shares: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

F1 · price: Grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of AYTU common stock. The RSUs vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 1, 2022, and 1/12 on the first day of each quarter thereafter, such that the RSUs will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.

SEC source: 0000919574-21-003313 · ownership.xml · nonDerivative · entry 4

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director

Boyd Steven · CIK 0001706140 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote 1

Disclosed balance after: 1,342,378

F2 · kind: The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.

SEC source: 0000919574-21-003313 · ownership.xml · nonDerivative · entry 3

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director

Boyd Steven · CIK 0001706140 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,342,378

F2 · kind: The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.

F2 · price: The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.

F1 · ownership.direct: The reported shares of common stock (the "Shares") of Aytu BioPharma, Inc. (the "Issuer") are directly held by Armistice s (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

SEC source: 0000919574-21-003313 · ownership.xml · nonDerivative · entry 2

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director

Boyd Steven · CIK 0001706140 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote 1

Disclosed balance after: 1,340,293

F2 · kind: The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.

SEC source: 0000919574-21-003313 · ownership.xml · nonDerivative · entry 1

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director

Boyd Steven · CIK 0001706140 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,340,293

F2 · kind: The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.

F2 · price: The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.

F1 · ownership.direct: The reported shares of common stock (the "Shares") of Aytu BioPharma, Inc. (the "Issuer") are directly held by Armistice s (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

SEC source: 0000912282-25-001096 · form5.xml · nonDerivative · entry 2

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Alpha Venture Capital Parner, LP

Disclosed balance after: 0

F1 · kind: The Reporting Person's purchase and sale of AYTU common shares (the "Shares") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 209 Shares sold on December 30, 2020, with the Reporting Person's purchase of 10,000 Shares on November 18, 2020. After taking into consideration the Issuer's 10:1 reverse stock split on December 10, 2020, the price for the November 18, 2020, purchase was $9.23 per share, or a total purchase price of $1,929.07 for 209 Shares. The total sale price of 209 Shares on December 30, 2020, was $1,256.09. THE REPORTING PERSON DID NOT REALIZE ANY PROFIT IN CONNECTION WITH THE SHORT-SWING PURCHASE AND SALE.

SEC source: 0000919574-20-007541 · ownership.xml · nonDerivative · entry 2

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director

Boyd Steven · CIK 0001706140 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote 1

Disclosed balance after: 1,333,334

SEC source: 0000919574-20-007541 · ownership.xml · nonDerivative · entry 1

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director

Armistice Capital Master Fund Ltd. · CIK 0001633584 · Director

Boyd Steven · CIK 0001706140 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,333,334

F1 · ownership.direct: The reported securities of Aytu BioScience, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000912282-25-001096 · form5.xml · nonDerivative · entry 1

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Alpha Venture Capital Management, LLC

Disclosed balance after: 50

F1 · kind: The Reporting Person's purchase and sale of AYTU common shares (the "Shares") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 209 Shares sold on December 30, 2020, with the Reporting Person's purchase of 10,000 Shares on November 18, 2020. After taking into consideration the Issuer's 10:1 reverse stock split on December 10, 2020, the price for the November 18, 2020, purchase was $9.23 per share, or a total purchase price of $1,929.07 for 209 Shares. The total sale price of 209 Shares on December 30, 2020, was $1,256.09. THE REPORTING PERSON DID NOT REALIZE ANY PROFIT IN CONNECTION WITH THE SHORT-SWING PURCHASE AND SALE.

F2 · balance_after: Represents total Shares held following stock splits on June 30, 2016 (12:1), August 25, 2017 (20:1), August 13, 2018 (20:1), December 10, 2020 (10:1) and January 6, 2023 (20:1).

SEC source: 0001654954-20-006581 · section16.xml · derivative · entry 2

MACALUSO MICHAEL · CIK 0001096423 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,105

Underlying: Common Stock · 40,000 shares

Expires 2030-06-07

F2 · derivative.exercise_date: 100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates.

SEC source: 0001654954-20-006585 · section16.xml · derivative · entry 2

Green David A · CIK 0001372822 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-06-07

F2 · derivative.exercise_date: 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024.

SEC source: 0001654954-20-006585 · section16.xml · nonDerivative · entry 1

Green David A · CIK 0001372822 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,250

F1 · price: These are restricted shares. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024

SEC source: 0001654954-20-006583 · section16.xml · derivative · entry 2

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,275

Underlying: Common Stock · 100,000 shares

Expires 2030-06-07

F2 · derivative.exercise_date: 2. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024.

SEC source: 0001654954-20-006583 · section16.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 975,048

F1 · price: 1. These are restricted shares. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024